Peptides DB
Research-centric peptide and protocol reference hub

Vasopressin record · updated 6h ago

Neuro & moodMetabolic & appetiteGrade A · human clinicalResearch use only
All 31 studiesJump to the evidenceCompare
What is Vasopressin used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: Vasopressin receptor agonist (V1a, V1b, V2)

Primarily researched for · Neuro & moodRoute · Subcutaneous injection

Development stage

where Vasopressin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 115 registered trials. It describes the research record, not a recommendation.

Identity
NameVasopressin
Chain length—
Molecular weight1,084.2 Da
FormulaC46H65N15O12S2
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 644077. No verified residue count for this compound.

Pharmacology
MechanismVasopressin receptor agonist (V1a, V1b, V2)
RouteSubcutaneous injection
Half-life~10–20 min
Time to peak~30 min
Duration~2-8 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 20, 2026. How this works →
Research stats
Total studies31
Human / animal / cellular9 / 9 / 7
Highest trial phasePhase 4
Years covered2011–2026
Latest study4d ago
Publication history
20112026
Research funding
6,325 NIH projects · $24.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports5,775
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

31 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
External validation reveals poor calibration despite preserved discrimination for a vasopressin treatment-signal prediction model across ICU databases
FindingAUROC was 0.768 (95% CI 0.734–0.804) internally.
review2026Full text read0.80
Transcriptomic Remodeling of the Hypothalamic Paraventricular Nucleus in Pregnant Spontaneously Hypertensive Rats: Autonomic Dysfunction and Neuroimmune Signature
Finding951 DEGs in pregnant SHRs compared to 33 DEGs in pregnant Wistars.
Animal2026Full text read0.70
The β-carboline derivative Carbacetam attenuates mortality and neuroendocrine dysfunction in a rodent model of traumatic brain injury: A multi-target pharmacological and molecular docking study.
Finding30-day survival probability of 81.2% with Carbacetam vs 33.2% in controls.
Animal2026Full text read0.80
Optimization of esterase production from Monascus purpureus Y146 by artificial neural network-genetic algorithm and its application in flavor enhancement of fermented wine.
FindingEsterase activity of 1248.02 U/mL, a 4.68-fold increase.
In vitro2026Full text read0.80
CRISPR-Cas9 mediated adiA knockout in Hafnia paralvei: Implications for agmatine production and acid stress survival in a fermented dairy matrix.
FindingAgmatine accumulation occurs exclusively under acidic conditions.
In vitro2026Full text read0.80
Primate-specific regulation of the human glycosphingolipid gatekeeper UGCG.
FindingNot reported in abstract.
In vitro2026Partial text0.50
Deep learning-mediated detection of accelerated water drinking after aquaresis in V1b vasopressin receptor knockout mice
FindingNot reported in abstract.
Animal2026Full text read0.80
Design of liquid crystalline nanoparticles: Linking composition to membrane interactions and siRNA delivery.
FindingsiRNA delivered by LCN-P407 showed > 1.7-fold greater uptake than that administered by LCN-P188.
In vitro2026Full text read0.70
Fetal microglia show region-specific and morphology-dependent sex differences in their responsiveness to prenatal maternal stress
FindingNot reported in abstract.
Animal2026Full text read0.70
Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: Research Summary.
TakeawayNot reported in abstract.
review2026Title only0.10
Arginine Treatment and Sickle Cell Disease Pain-A Great STArT, but a Hard End Point.
TakeawayNot reported in abstract.
—2026Title only0.10
Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.
TakeawayNot reported in abstract.
Human2026Title only0.10

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Vasopressin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Vasopressin is discussed should be drawn from it.